Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10

Ayoma Attygalle, Rajai Al-Jehani, Tim C. Diss, Phillipa Munson, Hongxiang Liu, Ming-Qing Du, Peter G. Isaacson, and Ahmet Dogan

Angioimmunoblastic T-cell lymphoma (AITL) is a systemic disease involving lymph nodes, spleen, and bone marrow. Although the histologic features have been well described, the diagnosis is often challenging, as there are no specific phenotypic or molecular markers available. This study shows that the neoplastic cells of AITL can be identified by aberrant CD10 expression. Archival material from 30 cases of AITL, 10 cases of peripheral T-cell lymphoma unspecified (PTL), and 10 cases of reactive lymphoid hyperplasia were reviewed. Single and double immunostaining for CD3, CD4, CD8, CD20, CD21, CD10, BCL6, Ki67, and LMP-1 in situ hybridization for Epstein-Barr early region and polymerase chain reaction (PCR) for T-cell receptor gamma chain gene and immunoglobulin heavy chain gene were performed. Three overlapping histologic patterns with hyperplastic follicles, depleted follicles, or without follicles were identified in AITL. Of the 30 cases of AITL, 27 contained CD10+ T cells. No CD10+ T cells were present in the cases of PTL or reactive hyperplasia. PCR confirmed a monoclonal or oligoclonal T-cell population in 29 of 30 cases of AITL and a monoclonal B-cell population in 6 cases. Analysis of microdissected CD10+ single cells showed that they belonged to the neoplastic clone. In conclusion CD10 is a phenotypic marker that specifically identifies the tumor cells in 90% of AITL, including the early cases. The presence of these cells distinguishes AITL from other PTLs. This finding provides an objective criterion for accurate and early diagnosis of AITL. (Blood. 2002; 99:627-633)

© 2002 by The American Society of Hematology

Introduction

Angioimmunoblastic T-cell lymphoma (AITL) is a systemic disease involving lymph nodes, spleen, and bone marrow.1 2 Histologically, the lymph nodes show partial or total obliteration of the normal architecture by a polymorphic infiltrate of lymphocytes, plasma cells, and eosinophils and proliferation of venules and follicular dendritic cells (FDCs).3 5 In many instances cytologic features of malignancy are not readily identifiable. For this reason the disease was first described as an atypical reactive process, angioimmunoblastic lymphadenopathy.1 However, cytogenetic and molecular studies have consistently shown clonal chromosomal abnormalities6 and monoclonal or oligoclonal T-cell populations in most cases, which strongly supports a T-cell neoplasm.7 8 Some cases also contain oligoclonal or monoclonal B-cell populations,9 that are attributed to the expansion of B cells infected with Epstein-Barr virus (EBV),9 possibly secondary to the immunodeficiency associated with the T-cell lymphoma. Whether AITL is a neoplastic process from the inception or whether it is preceded by a polyclonal or oligoclonal reactive state, angioimmunoblastic lymphadenopathy is a matter of debate.4 10 11

The outcome for patients with AITL remains dismal with a median survival of less than 3 years.12 14 There are 2 major reasons for difficulties in dealing with this disease. First, although the histologic features of AITL are well described, there is considerable morphologic overlap with reactive lymphoid proliferations and other lymphomas. Unlike many other lymphomas, no specific phenotypic or molecular markers have been identified so far to assist the diagnosis that often leads to delayed or wrong histologic diagnosis, denying the patient the chance of early treatment.

Second, very little is known about the biology of the disease. This is partly due to the lack of objective diagnostic criteria, but, more critically, in most cases the tumor cell population cannot be specifically identified within the polymorphic reactive and inflammatory cells. In a subset of the cases it is thought that perivascular collections of CD3+ cells with clear cytoplasm represent the neoplastic population.15

In this paper we show that the neoplastic cells in most cases of AITL can be identified by aberrant expression of CD10. The presence of such a marker has provided the opportunity to establish objective criteria for the diagnosis of this disease, even in its early stage of evolution, as well as the ability to investigate the biologic characteristics of the neoplastic T cells.

Materials and methods

Tissues

Thirty-two formalin-fixed, paraffin-embedded, lymph node biopsies from 30 cases of AITL, 10 blocks from 10 cases of nodal peripheral T-cell lymphoma unspecified (PTL), and 10 blocks from 10 cases of reactive lymph node hyperplasia were retrieved from the archives of the Department of Histopathology, University College London Hospital. The histology was reviewed and the diagnosis was confirmed in each case. Of the cases of AITL, 4 were local cases, whereas the remaining 26 cases had been referred from other centers for a second opinion. The original diagnosis of the referring center was obtained where possible.

From the Department of Histopathology, Royal Free and University College Medical School, London, United Kingdom.

Supported by a project grant from the Leukaemia Research Fund.

Reprints: Ahmet Dogan, Department of Histopathology, Royal Free and University College Medical School, Rockefeller Bldg, University St, London WC1E 6JJ, United Kingdom; e-mail: a.dogan@ucl.ac.uk.

© 2002 by The American Society of Hematology
Immunohistochemistry

Paraffin sections (3 μm) were immunostained by the streptavidin immunoperoxidase method (ChemMate Streptavidin Peroxidase kit [Dako, Cambridge, United Kingdom] and DAB chromogen [Sigma, Poole, United Kingdom]) after heat-mediated antigen retrieval as previously described.16 Primary antibodies included CD3 (polyclonal anti-CD3; Dako), CD20 (L26; Dako), CD4 (1F6; Vector Labs, Peterborough, United Kingdom), CD8 (C8/144B; Dako), CD20, CD79a (JCB117; Dako), CD21 (1F8; Dako), Ki67 (MBI-1; Dako), LMP-1 (CS1-4; Dako), and CD10 (56C6; Novacabra Labs, Newcastle, United Kingdom).

Sequential double-staining was performed by using CD20/CD10, CD3/CD10, CD4/CD10, and Ki67/CD10. The first antibody was revealed with peroxidase and the second with alkaline phosphatase with a fast blue chromogen (Fast Blue/Naphthol AS-BI; Sigma) in each case.17 No counterstain was used. The approximate ratio of CD10+ T cells to all T cells was assessed from serial sections immunostained for CD3 and CD20/CD10.

The proliferation fraction was calculated by counting 500 CD10+ cells in 5 to 7 different areas of the lymph node on sections double immunostained for Ki67/CD10.

In situ hybridization for EBV

In situ hybridization was carried out with a polymerase chain reaction (PCR)-generated EBV DNA probe labeled with digoxigenin, followed by incubation with antidigoxigenin-AP (Boehringer Mannheim, Germany) and visualization with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium as previously described.18

PCR for T-cell receptor γ chain gene and immunoglobulin heavy chain gene

PCR was performed to analyze clonal expansion of T cells and B cells. DNA was extracted from paraffin sections by using proteinase K digestion without subsequent organic extraction as previously described.17 T-cell clonal expansion was detected by analysis of T-cell receptor γ (TCR-γ) chain gene rearrangement. Duplicate aliquots of each sample were analyzed for rearrangement by using 2 sets of primers.17 Set 1 consisted of primers directed to the Vγ-1, Vγ-2, Vγ-3, and Jγ-1/2 segments and set 2 of primers targeted Vγ-1, Vγ-2, Vγ-3, and Jγ-2. Forty cycles of PCR of 30 seconds at 93°C, 30 seconds at 55°C, and 1 minute at 73°C were performed after hotstart by addition of Taq polymerase at 55°C after 5 minutes at 95°C. The final extension time was extended to 6 minutes. DNA extracted from a paraffin block of a T-cell lymphoma was used as a positive control and a reaction without template DNA was run as a negative control in all experiments.

B-cell clonal expansion was detected by analysis of immunoglobulin heavy (IgH) chain gene rearrangement. Samples were subjected to amplification of the IgH chain gene by using a seminested protocol with primers directed to the framework 3 and joining regions of the gene, as described.19 Test samples were studied in parallel with appropriate positive and negative controls. PCR products were analyzed on 10% polyacrylamide minigels, stained with ethidium bromide, and viewed under UV light.

Microdissection of CD10+ cells with laser capture microscopy

Microdissection of CD10+ cells and CD10- areas was performed by using PixCell II Laser Capture Microdissection system (Arcturus, Mountain View, CA), using 5-μm sections immunostained for CD10.20 A laser beam diameter of 7.5 μm was used to achieve single cell microdissection. Between 30 and 50 single cells were microdissected onto Capsure Transfer film (Arcturus). The DNA was extracted and PCR for TCR-γ chain gene was performed as described above. Each PCR reaction was estimated to contain DNA from 6 CD10+ cells.

Cloning and sequencing

To confirm the monoclonal nature of dominant bands and the clonal identity of PCR products of the same size from whole sections and microdissected CD10+ cells, the individual bands were isolated, cloned, and sequenced as previously described.18 PCR products were purified by using QIA Quick Gel Extraction Kit (QIAGEN, West Sussex, United Kingdom), then ligated into the pGEM-T vector and transformed into JM109 competent cells (Promega, Southampton, United Kingdom). The transformed cells were selected on LB-ampicillin agar plates containing X-gal and isopropyl β-D-thiogalactoside. White colonies were screened by using PCR with vector primers (Sp6 and T7). The PCR products showing the expected insert size were sequenced in both directions by using an ABI sequencer with dRhodamine terminators (Perkin-Elmer, Foster City, CA). Five to 10 clones from each PCR band were sequenced.

Results

Clinical features

The clinical features are summarized in Table 1. There were 17 men and 13 women between the ages of 37 and 84 years. Most patients presented with generalized lymphadenopathy. Other clinical features included weight loss, fever, skin rash, anemia, and hepatosplennomegaly. The initial histologic diagnosis wasAITL in only 13 cases. In the remaining 17 cases the diagnoses included reactive lymphoid hyperplasia (4 cases), T-cell rich B-cell lymphoma (4 cases), and other lymphomas (8 cases).

Histology

Angioimmunoblastic T-cell lymphoma. The histologic features are summarized in Table 2. At the time of initial diagnosis, the cases could be separated into 3 overlapping patterns. In pattern I (6 cases) there was partial preservation of the lymph node architecture. Hyperplastic B-cell follicles with poorly developed mantle zones and ill-defined borders were easily identifiable in the cortex of the lymph node. These structures merged into the expanded paracortex containing a polymorphic infiltrate of lymphocytes and transformed large lymphoid blasts, plasma cells, macrophages, and eosinophils within a prominent vascular network. Increase in FDCs was not evident (Figure 1A).

Pattern II (10 cases) was characterized by loss of normal architecture except for the presence of occasional depleted follicles with concentrically arranged FDCs. In some cases FDC proliferation extending beyond the follicles could be identified. The rest of the node showed a polymorphic infiltrate with increased numbers of transformed lymphoid blasts and vascular proliferation similar to that described for pattern I (Figure 1C).

In pattern III (14 cases) the normal architecture was completely effaced and no B-cell follicles could be identified. Prominent irregular proliferation of FDCs could be seen in hematopoietic and eosin–stained sections in most cases, and this situation was accompanied by extensive vascular proliferation and a polymorphic infiltrate similar to that seen in patterns I and II (Figure 1E).

In 16 cases perivascular collections of cells with clear cytoplasm were evident. In 2 cases in which consecutive biopsies from the same patient were available, the earlier biopsies showed pattern II and the later pattern III.

Peripheral T-cell lymphoma. All cases of PTL showed effacement of nodal architecture with a relatively monomorphic infiltrate of medium to large atypical lymphoid cells. A moderate degree of vascular proliferation was present without the prominent arborizing networks seen inAITL. FDC proliferation was not a feature.

Reactive lymph node hyperplasia. All reactive lymph nodes showed preservation of the architecture and hyperplastic lymphoid follicles with moderate paracortical expansion.
lymph node biopsies) there were concentrations of CD10 identified within meshworks of CD21 small B cells, mostly not associated with germinal centers, could be seen out the entire lymph node and formed perivascular aggregates, whereas in pattern III they showed a more haphazard arrangement, with the paracortex, often surrounding proliferating small vessels, was a population of smaller strongly staining lymphoid cells at the outer rim of the germinal center that extended into the paracortex. In all but 3 cases (45%) there were varying numbers of CD20 lymphoid cells, strongly suggesting that these were T cells (Figure 3A-F).

Further double-staining experiments showed that the CD10+ T cells were confined to the outer rim of the germinal center that extended into the paracortex. In pattern II and III isolated CD10+ germinal center cells there were clusters of "purple" cells coexpressing CD3 and CD10. The ratio of CD10+ T cells to all T cells for each case is shown in Table 2.

Double staining with CD20 followed by CD10 was performed on paraffin sections. Sequential double staining was performed on cytologic sections. Immunohistochemistry

Angioimmunoblastic T-cell lymphoma. In pattern I sprouts of CD21+ FDCs extended beyond the confines of the CD21+ germinal centers and occasionally enveloped small blood vessels (Figure 1B). Paracortical T cells, including some transformed blasts, expressed CD3 and predominantly CD4. A smaller CD8+ population was present. Preserved germinal centers expressed CD20 and CD10. In addition to CD10+ germinal center cells there was a population of smaller strongly staining lymphoid cells at the outer rim of the germinal center that extended into the paracortex (Figure 2A-B).

In pattern II, CD21+ FDCs extended beyond the follicles into the paracortex, often surrounding proliferating small vessels, whereas in pattern III they showed a more haphazard arrangement, surrounding the arborizing small vessels (Figure 1D,F). In both patterns II and III, CD20, IgM, and IgD+ but CD10− clusters of small B cells, mostly not associated with germinal centers, could be identified within meshworks of CD21+ FDCs. In all but 3 cases (45% lymph node biopsies) there were concentrations of CD10+ T cells around the CD20+ B-cell clusters as described for pattern I (Figure 2C-F). In addition isolated CD10+ T cells were scattered throughout the entire lymph node and formed perivascular aggregates, corresponding to the clear cells noted in hematoxylin and eosinstained sections (Figure 2F). CD10+ was also expressed by granulocytes most of which were within blood vessels. Their characteristic cytologic features easily distinguished them from the CD10+ lymphoid cells. In biopsies showing patterns II and III isolated transformed CD20+ blasts were identified within the predominantly CD3+ infiltrate.

PTL and reactive lymph node hyperplasia. No CD10+ lymphoid cells were present in any of the cases of PTL, whereas in reactive lymph nodes CD10+ cells were confined to the germinal centres.

Sequential double staining

Double staining with CD20 followed by CD10 was performed on all lymph node biopsies to show that the lymphoid cells expressing CD10 were not germinal center B cells. In 28 of 32 biopsies (27 of 30 cases) there were varying numbers of CD20−, CD10− lymphoid cells, strongly suggesting that these were T cells (Figure 3A-F). Double staining with CD79a and CD10 gave identical results. The T-cell phenotype of the CD20−, CD10− lymphoid cells was also confirmed by CD3/CD10 double staining that showed a population of "purple" cells coexpressing CD3 and CD10. The ratio of CD10+ T cells to all T cells for each case is shown in Table 2.

Further double-staining experiments showed that the CD10+ T cells expressed CD4 but not CD8, whereas a subset of the CD10+ T cells showed nuclear positivity for BCL6 in all cases.
with CD10+ T cells. Double staining of the CD10+ cells with Ki-67 showed that these phenotypically aberrant T cells had a low proliferation fraction (Table 2).

In situ hybridization for EBV–Epstein-Barr early region

All cases of AITL showed hybridization for EBV–Epstein-Barr early region (EBER) in a subset of the cells. The number of cells expressing EBV-EBER varied markedly from case to case; in some only scattered cells were positive, and in others numerous large blasts were labeled. The distribution of EBER+ cells was similar to the distribution of large B blasts and did not correspond to the clusters of CD10+ T cells.

PCR for TCR-γ and IgH gene rearrangement

The results of PCR for TCR-γ gene and IgH chain gene are shown in Table 2 and Figure 4. There was a monoclonal (1-2 dominant bands) or oligoclonal (3-4 dominant bands) T-cell population in all cases except one. Six of the cases also showed evidence of a monoclonal B-cell population. In all of these cases numerous EBV-infected transformed lymphocytes were present.

Single-cell microdissection

To investigate whether the CD10+ T cells were part of the neoplastic clone, we microdissected 30 to 50 CD10+ cells from 5 cases (Figure 5) and performed PCR for TCR-γ gene. In each case, analysis of the PCR products from microdissected cells gave a dominant band(s) identical in size to that observed for the PCR performed on whole sections (Figure 4). In contrast DNA extracted from areas lacking CD10+ cells showed a polyclonal ladder or smear.

Cloning and sequencing of PCR products

The cloning and sequencing of the dominant bands isolated from PCR products of 3 cases showed a dominant clone with identical

![Figure 1. Histologic features and CD21 expression in 3 histologic patterns of AITL.](image)

**Table 2. Summary of histologic features, immunophenotype, and molecular analysis of AITL cases**

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Pattern*</th>
<th>CD10/CD3† (%)</th>
<th>Clear cells‡</th>
<th>CD10/Ki67§ (%)</th>
<th>TCR PCR</th>
<th>IgH PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>I</td>
<td>5</td>
<td>Absent</td>
<td>0</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>2</td>
<td>I</td>
<td>5</td>
<td>Absent</td>
<td>16</td>
<td>M</td>
<td>P</td>
</tr>
<tr>
<td>3</td>
<td>I</td>
<td>10</td>
<td>Present</td>
<td>O</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>4</td>
<td>I</td>
<td>10</td>
<td>Absent</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>5</td>
<td>I</td>
<td>20</td>
<td>Present</td>
<td>8</td>
<td>M</td>
<td>P</td>
</tr>
<tr>
<td>6</td>
<td>I</td>
<td>0</td>
<td>Absent</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>7</td>
<td>II</td>
<td>5</td>
<td>Absent</td>
<td>P</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>8</td>
<td>II</td>
<td>5</td>
<td>Absent</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>9</td>
<td>II</td>
<td>5</td>
<td>Absent</td>
<td>11</td>
<td>M</td>
<td>P</td>
</tr>
<tr>
<td>10</td>
<td>II</td>
<td>10</td>
<td>Present</td>
<td>19</td>
<td>O</td>
<td>P</td>
</tr>
<tr>
<td>11</td>
<td>II</td>
<td>10</td>
<td>Present</td>
<td>M</td>
<td>M</td>
<td>P</td>
</tr>
<tr>
<td>12</td>
<td>II</td>
<td>15</td>
<td>Present</td>
<td>M</td>
<td>M</td>
<td>P</td>
</tr>
<tr>
<td>13</td>
<td>II</td>
<td>20</td>
<td>Absent</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>14</td>
<td>II</td>
<td>20</td>
<td>Absent</td>
<td>O</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>15A</td>
<td>II</td>
<td>5</td>
<td>Absent</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>15B</td>
<td>III</td>
<td>5</td>
<td>Present</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>16A</td>
<td>II</td>
<td>0</td>
<td>Absent</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>16B</td>
<td>III</td>
<td>0</td>
<td>Absent</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>17A</td>
<td>III</td>
<td>5</td>
<td>Present</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>18A</td>
<td>III</td>
<td>5</td>
<td>Present</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>19A</td>
<td>III</td>
<td>5</td>
<td>Present</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>20A</td>
<td>III</td>
<td>5</td>
<td>Present</td>
<td>O</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>21A</td>
<td>III</td>
<td>10</td>
<td>Absent</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>22A</td>
<td>III</td>
<td>10</td>
<td>Absent</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>23A</td>
<td>III</td>
<td>20</td>
<td>Present</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>24A</td>
<td>III</td>
<td>20</td>
<td>Present</td>
<td>M</td>
<td>NA</td>
<td>P</td>
</tr>
<tr>
<td>25A</td>
<td>III</td>
<td>20</td>
<td>Present</td>
<td>10</td>
<td>M</td>
<td>P</td>
</tr>
<tr>
<td>26A</td>
<td>III</td>
<td>30</td>
<td>Absent</td>
<td>11</td>
<td>O</td>
<td>P</td>
</tr>
<tr>
<td>27A</td>
<td>III</td>
<td>30</td>
<td>Present</td>
<td>19</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>28A</td>
<td>III</td>
<td>30</td>
<td>Present</td>
<td>M</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>29A</td>
<td>III</td>
<td>30</td>
<td>Present</td>
<td>O</td>
<td>P</td>
<td>P</td>
</tr>
<tr>
<td>30A</td>
<td>III</td>
<td>0</td>
<td>Present</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
</tbody>
</table>

TCR indicates T-cell receptor-γ chain gene; PCR, polymerase chain reaction; IgH, immunoglobulin heavy chain gene; M, monoclonal; O, oligoclonal; P, polyclonal; NA, no amplification.

*The histologic pattern as described in “Results.”
†Percentage of CD10+ and CD3+ T cells.
‡Cases containing aggregates of atypical lymphoid cells with clear cytoplasm.
§Percentage of CD10+ cells expressing Ki67.
sequence, confirming the monoclonal nature of all cases examined. For each of the 3 cases the dominant clone from the whole sections and from the microdissected CD10+ cells were identical (Table 3).

Discussion

The histologic diagnosis of AITL may be difficult as is shown by the large error rate (13 of 26; 50%) in referred cases in our series. This error rate is especially true in the early phase of the disease when preservation of follicles and only slight expansion of the paracortex are present. The expanded CD21+ FDC meshwork is very helpful in making the diagnosis but can be subtle. Molecular investigation and, in many instances, repeated biopsies may be required to reach a confident diagnosis. In this study we have shown that CD10 is a phenotypic marker that specifically identifies the tumor cells in 90% of AITLs, including, importantly, the early cases with pattern I histology. We believe that this marker provides an objective criterion for the diagnosis of AITL and should greatly assist in the diagnosis of this disorder.

Moreover, the presence of these cells distinguishes AITL from other more usual PTLs as none of the PTLs we have studied showed CD10 expression. Recently, de Leval et al21 have reported 3 cases of PTL with follicular growth pattern. In 2 of the cases there was CD10 expression by T cells. It is possible that these cases were also pattern I AITL without FDC proliferation.

The CD10-expressing T cells must be distinguished from germinal center B cells especially in cases with pattern I histology. They are typically seen at the margins of B-cell follicles as
small-to-medium-sized lymphoid cells with crisp membrane staining in contrast to the larger follicle center B cells that stain more diffusely and with less intensity. In more advanced cases with pattern II or III histology the CD10+ T cells are more diffusely distributed as single cells and in small clusters. Double staining confirmed that these cells are CD3 and CD4 distributed as single cells and in small clusters. Second, the clusters of large cells with clear cytoplasm, which occur in some cases and which are widely regarded to represent the neoplastic clone in AITL, were consistently down-regulated. The reasons for this down-regulation currently remain obscure.

The cases with the histologic patterns II and III fulfill the conventional criteria for the diagnosis of AITL. Thus, there was clinical evidence of a systemic disease characterized by generalized lymphadenopathy, hepatosplenomegaly, and anemia together with characteristic histologic features in lymph node biopsies. These features include effacement of lymph node architecture by a polymorphic infiltrate of lymphoid cells, proliferation of FDCs and small vessels, the presence of varying numbers of EBV-infected transformed B cells, and the presence of clusters of large transformed cells with clear cytoplasm. In addition there was molecular evidence for the presence of monoclonal or oligoclonal T-cell populations. Whether the cases falling into histologic pattern I can also be considered within the same spectrum is more controversial.

The presence of hyperplastic follicle centers in otherwise typical AITL was first described by Ree et al, who reported progression of 2 such cases into typical AITL. We observed the CD10+ T cells in all histologic patterns, including the cases with hyperplastic germinal centres. These pattern I cases had the smallest number of CD10+ T cells, whereas pattern III cases had the most. In 2 cases, in which 2 consecutive biopsies were available, we observed progression from pattern II to pattern III. These observations strongly support that all 3 histologic patterns of AITL described in this study are part of the same disease process and that the histologic patterns I, II, and III form a biologic continuum.

In 5 cases in which microdissection was performed only the CD10+ T cells were clonal, and we failed to detect the presence of the clonal T cells in microdissected CD10- areas. Thus, the proportion of neoplastic T cells in AITL would appear to be small (5%-30%), and it appears that most of the lymph node enlargement is accounted for by reactive cells similar to what occurs in Hodgkin lymphoma. In this context it will be interesting to investigate the cytokine profile of the CD10+ T cells.

Table 3. Results of cloning and sequencing of dominant bands obtained from PCR amplification of TCR-γ chain gene from whole lymph node sections and microdissected CD10+ cells

<table>
<thead>
<tr>
<th>Case no.</th>
<th>PCR band</th>
<th>Whole lymph node*</th>
<th>Microdissected CD10+ cells†</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Upper</td>
<td>4/6</td>
<td>6/6</td>
</tr>
<tr>
<td></td>
<td>Lower</td>
<td>3/6</td>
<td>6/6</td>
</tr>
<tr>
<td>26</td>
<td>Upper</td>
<td>3/5</td>
<td>4/6</td>
</tr>
<tr>
<td></td>
<td>Lower</td>
<td>11/13</td>
<td>8/9</td>
</tr>
<tr>
<td>28</td>
<td>Upper</td>
<td>7/9</td>
<td>5/7</td>
</tr>
<tr>
<td></td>
<td>Lower</td>
<td>10/10</td>
<td>Not done</td>
</tr>
</tbody>
</table>

PCR indicates polymerase chain reaction; TCR-γ, T-cell receptor-γ.

*The number of clones with identical TCR-γ chain gene sequence/total number of clones sequenced.
†The number of clones with TCR-γ chain gene sequence identical to the dominant sequence obtained from the whole section PCR/total number of clones sequenced.
CD10 is a 100-kd, type II, integral membrane protein with neutral endopeptidase activity. The physiologic role of CD10 is thought to involve hydrolysis of polypeptides such as inflammatory mediators in the extracellular milieu. In peripheral lymphocytes, CD10 expression is limited to follicle center B cells that have a high rate of apoptosis. In a study, Cutrona et al have demonstrated expression of CD10 is also induced in T cells going through apoptosis in healthy or HIV-infected individuals. This apoptosis was seen only by flow cytometric analysis and not by immunohistochemistry, suggesting that the protein levels may be too low for detection on tissue sections. Those researchers have proposed that expression of CD10 may regulate apoptosis by interfering with negative or positive signals present in the extracellular environment. It is possible that aberrant CD10 expression in neoplastic T cells in AITL may be an indicator of disturbed apoptotic cell death. We observed that CD10+ neoplastic T cells have a low proliferation fraction. This is analogous to low-grade B-cell lymphomas such as the follicular lymphoma in which prevention of cell death by overexpression of antiapoptotic BCL2 protein rather than acquisition of high proliferative activity is considered to be the critical molecular event. An attractive hypothesis is that, analogous to follicular lymphoma, AITL is a biologically indolent/low-grade tumor-causing disease and that death is by immune deregulation rather than increased tumor load. This hypothesis is supported by the clinical observations suggesting that some patients do respond to immunosuppressive treatment.

In conclusion, we have demonstrated that CD10 is a marker of neoplastic T cells in AITL. Early and accurate diagnosis of AITL can now be achieved by the simple expedient of immunostaining for CD10, a simple test that can be performed in any histopathology laboratory. More importantly, identification of a specific marker for the neoplastic T cells in AITL, for the first time, gives us the opportunity to investigate the biology of this disease with a view to devise novel therapeutic approaches.

Acknowledgments

We thank Professor S. Lakhani and the Ludwig Institute for Cancer Research for access to the Laser Capture Microscope and R. A. Hamoudi, Institute of Cancer Research, London, for assistance with sequencing.

References

Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10

Ayoma Attygalle, Rajai Al-Jehani, Tim C. Diss, Phillipa Munson, Hongxiang Liu, Ming-Qing Du, Peter G. Isaacson and Ahmet Dogan